Dr. Herbst on the Next Generation of Lung Cancer Trials

Roy S. Herbst, MD, PhD
Published: Wednesday, Oct 01, 2014

Roy S. Herbst, MD, PhD, professor, Yale Cancer Center, chief of medical oncology, Smilow Cancer Hospital at Yale-New Haven, discusses next generation lung cancer trials.

The next generation of lung cancer trials will try to match new biomarkers with new therapeutic agents.

The BATTLE trials, which began in 2005, had all patients freshly biopsied and randomized to 1 of 4 arms of therapy. Researchers began BATTLE-1 with hypotheses regarding biomarkers and outcomes and analyzed data in real time. This trial identified relationships between markers and drugs, including the correlation between VEGFR2 and activity of angiogenesis inhibitors.

Roy S. Herbst, MD, PhD, professor, Yale Cancer Center, chief of medical oncology, Smilow Cancer Hospital at Yale-New Haven, discusses next generation lung cancer trials.

The next generation of lung cancer trials will try to match new biomarkers with new therapeutic agents.

The BATTLE trials, which began in 2005, had all patients freshly biopsied and randomized to 1 of 4 arms of therapy. Researchers began BATTLE-1 with hypotheses regarding biomarkers and outcomes and analyzed data in real time. This trial identified relationships between markers and drugs, including the correlation between VEGFR2 and activity of angiogenesis inhibitors.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Novel Therapeutic Options for Lung Neuroendocrine TumorsMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x